Summary
Global Markets Direct’s, ‘Nektar Therapeutics - Product Pipeline Review - 2016’, provides an overview of the Nektar Therapeutics’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Nektar Therapeutics, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Nektar Therapeutics
- The report provides overview of Nektar Therapeutics including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Nektar Therapeutics’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Nektar Therapeutics’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Nektar Therapeutics’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nektar Therapeutics
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nektar Therapeutics’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Nektar Therapeutics Snapshot 6
Nektar Therapeutics Overview 6
Key Information 6
Key Facts 6
Nektar Therapeutics - Research and Development Overview 7
Key Therapeutic Areas 7
Nektar Therapeutics - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Nektar Therapeutics - Pipeline Products Glance 16
Nektar Therapeutics - Late Stage Pipeline Products 16
Phase III Products/Combination Treatment Modalities 16
Nektar Therapeutics - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Nektar Therapeutics - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Nektar Therapeutics - Drug Profiles 21
etirinotecan pegol 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NKTR-181 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NKTR-214 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NKTR-171 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NKTR-173 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NKTR-195 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NKTR-218 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NKTR-223 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NKTR-230 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
NKTR-255 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Proteins for Hematological Disorders 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drug to Inhibit Kinase for Cancer 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Protein to Agonize Cytokine Receptor for Inflammation 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Protein to Agonize Cytokine Receptor for Viral Infections 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Nektar Therapeutics - Pipeline Analysis 38
Nektar Therapeutics - Pipeline Products by Target 38
Nektar Therapeutics - Pipeline Products by Route of Administration 39
Nektar Therapeutics - Pipeline Products by Molecule Type 40
Nektar Therapeutics - Pipeline Products by Mechanism of Action 41
Nektar Therapeutics - Recent Pipeline Updates 42
Nektar Therapeutics - Dormant Projects 50
Nektar Therapeutics - Discontinued Pipeline Products 51
Discontinued Pipeline Product Profiles 51
NKTR-105 51
NKTR-192 51
Nektar Therapeutics - Company Statement 52
Nektar Therapeutics - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57
List of Tables
Nektar Therapeutics, Key Information 6
Nektar Therapeutics, Key Facts 6
Nektar Therapeutics - Pipeline by Indication, 2016 8
Nektar Therapeutics - Pipeline by Stage of Development, 2016 10
Nektar Therapeutics - Monotherapy Products in Pipeline, 2016 11
Nektar Therapeutics - Partnered Products in Pipeline, 2016 12
Nektar Therapeutics - Partnered Products/ Combination Treatment Modalities, 2016 13
Nektar Therapeutics - Out-Licensed Products in Pipeline, 2016 14
Nektar Therapeutics - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
Nektar Therapeutics - Phase III, 2016 16
Nektar Therapeutics - Phase II, 2016 17
Nektar Therapeutics - Phase I, 2016 18
Nektar Therapeutics - Preclinical, 2016 19
Nektar Therapeutics - Discovery, 2016 20
Nektar Therapeutics - Pipeline by Target, 2016 38
Nektar Therapeutics - Pipeline by Route of Administration, 2016 39
Nektar Therapeutics - Pipeline by Molecule Type, 2016 40
Nektar Therapeutics - Pipeline Products by Mechanism of Action, 2016 41
Nektar Therapeutics - Recent Pipeline Updates, 2016 42
Nektar Therapeutics - Dormant Developmental Projects,2016 50
Nektar Therapeutics - Discontinued Pipeline Products, 2016 51
Nektar Therapeutics, Other Locations 55
Nektar Therapeutics, Subsidiaries 55
List of Figures
Nektar Therapeutics - Pipeline by Top 10 Indication, 2016 8
Nektar Therapeutics - Pipeline by Stage of Development, 2016 10
Nektar Therapeutics - Monotherapy Products in Pipeline, 2016 11
Nektar Therapeutics - Out-Licensed Products in Pipeline, 2016 14
Nektar Therapeutics - Pipeline by Target, 2016 38
Nektar Therapeutics - Pipeline by Route of Administration, 2016 39
Nektar Therapeutics - Pipeline by Molecule Type, 2016 40
Nektar Therapeutics - Pipeline Products by Mechanism of Action, 2016 41
